Priovant Wins a First FDA Nod for Brepocitinib in Dermatomyositis

With LISRAYA (brepocitinib) now on the U.S. market, Priovant Therapeutics has closed a decades-long gap in targeted therapy for dermatomyositis, and the approval carries structural implications for how small-molecule JAK inhibitors move through rare disease development pipelines. The FDA granted approval on 27 August 2026 for the 30 mg once-daily oral formulation in adults with dermatomyositis (DM), a rare systemic autoimmune disease marked by progressive muscle weakness and debilitating skin involvement.

LISRAYA is a first-in-class TYK2/JAK1 inhibitor, a mechanism that distinguishes it from broader pan-JAK agents and carries its own regulatory and pharmacovigilance considerations. For QA directors and regulatory leads managing post-approval commitments, the safety profile and class-effect labeling requirements for JAK inhibitors under 21 CFR Part 201 will warrant close attention as the product enters commercial distribution.

The approval rests on data from the Phase 3 VALOR trial, the largest dermatomyositis clinical trial conducted to date. The primary endpoint, the myositis Total Improvement Score, a composite measure spanning multiple disease domains, showed statistically significant benefit as early as Week 4, with effects sustained across the full 52-week study. Among patients on oral corticosteroids at baseline, 62% tapered to minimal or no steroid use by Week 52, versus 38% on placebo; 45% discontinued corticosteroids entirely, compared with 29% on placebo.

The Priovant-Roivant co-development model underpinning LISRAYA's path to approval is relevant context for plant heads and supply-chain leads. Roivant's subsidiary structure concentrates development risk within a dedicated entity while drawing on shared regulatory and manufacturing infrastructure, an arrangement that shapes how supply agreements, technology transfer, and GMP oversight responsibilities are allocated between partners. For organisations evaluating similar rare disease co-development structures, the LISRAYA programme offers a reference point on how regulatory strategy and manufacturing accountability can be distributed across a parent-subsidiary model.

Commercial availability is immediate; prescriptions can be submitted through the enrolment portal at lisrayahcp.com/enroll, with full prescribing information accessible at lisrayahcp.com/pi. A patient support programme, LISRAYA My Compass, provides cost assistance for eligible patients.

The 52-week durability data from VALOR will form the evidentiary baseline against which any post-marketing commitments and label update submissions are measured.

Source: Priovant Therapeutics via GlobeNewswire, 27 August 2026.